210 related articles for article (PubMed ID: 38340348)
1. Chromatin damage generated by DNA intercalators leads to degradation of RNA Polymerase II.
Espinoza JA; Kanellis DC; Saproo S; Leal K; Martinez JF; Bartek J; Lindström MS
Nucleic Acids Res; 2024 May; 52(8):4151-4166. PubMed ID: 38340348
[TBL] [Abstract][Full Text] [Related]
2. Role of Chromatin Damage and Chromatin Trapping of FACT in Mediating the Anticancer Cytotoxicity of DNA-Binding Small-Molecule Drugs.
Nesher E; Safina A; Aljahdali I; Portwood S; Wang ES; Koman I; Wang J; Gurova KV
Cancer Res; 2018 Mar; 78(6):1431-1443. PubMed ID: 29339544
[TBL] [Abstract][Full Text] [Related]
3. FACT facilitates chromatin transcription by RNA polymerases I and III.
Birch JL; Tan BC; Panov KI; Panova TB; Andersen JS; Owen-Hughes TA; Russell J; Lee SC; Zomerdijk JC
EMBO J; 2009 Apr; 28(7):854-65. PubMed ID: 19214185
[TBL] [Abstract][Full Text] [Related]
4. Nucleolar translocation of human DNA topoisomerase II by ATP depletion and its disruption by the RNA polymerase I inhibitor BMH-21.
Morotomi-Yano K; Yano KI
Sci Rep; 2021 Nov; 11(1):21533. PubMed ID: 34728715
[TBL] [Abstract][Full Text] [Related]
5. FACT subunit Spt16 controls UVSSA recruitment to lesion-stalled RNA Pol II and stimulates TC-NER.
Wienholz F; Zhou D; Turkyilmaz Y; Schwertman P; Tresini M; Pines A; van Toorn M; Bezstarosti K; Demmers JAA; Marteijn JA
Nucleic Acids Res; 2019 May; 47(8):4011-4025. PubMed ID: 30715484
[TBL] [Abstract][Full Text] [Related]
6. Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage.
Gieseler F; Bauer E; Nuessler V; Clark M; Valsamas S
Leukemia; 1999 Nov; 13(11):1859-63. PubMed ID: 10557063
[TBL] [Abstract][Full Text] [Related]
7. Poly(ADP-ribose) polymerases PARP1 and PARP2 modulate topoisomerase II beta (TOP2B) function during chromatin condensation in mouse spermiogenesis.
Meyer-Ficca ML; Lonchar JD; Ihara M; Meistrich ML; Austin CA; Meyer RG
Biol Reprod; 2011 May; 84(5):900-9. PubMed ID: 21228215
[TBL] [Abstract][Full Text] [Related]
8. TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma.
Jain M; Zhang L; He M; Zhang YQ; Shen M; Kebebew E
Endocr Relat Cancer; 2013 Jun; 20(3):361-70. PubMed ID: 23533247
[TBL] [Abstract][Full Text] [Related]
9. Histone chaperone FACT action during transcription through chromatin by RNA polymerase II.
Hsieh FK; Kulaeva OI; Patel SS; Dyer PN; Luger K; Reinberg D; Studitsky VM
Proc Natl Acad Sci U S A; 2013 May; 110(19):7654-9. PubMed ID: 23610384
[TBL] [Abstract][Full Text] [Related]
10. FACT maintains chromatin architecture and thereby stimulates RNA polymerase II pausing during transcription in vivo.
Žumer K; Ochmann M; Aljahani A; Zheenbekova A; Devadas A; Maier KC; Rus P; Neef U; Oudelaar AM; Cramer P
Mol Cell; 2024 Jun; 84(11):2053-2069.e9. PubMed ID: 38810649
[TBL] [Abstract][Full Text] [Related]
11. The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells.
Deng S; Yan T; Nikolova T; Fuhrmann D; Nemecek A; Gödtel-Armbrust U; Kaina B; Wojnowski L
Br J Pharmacol; 2015 May; 172(9):2246-57. PubMed ID: 25521189
[TBL] [Abstract][Full Text] [Related]
12. Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG.
Ehteda A; Simon S; Franshaw L; Giorgi FM; Liu J; Joshi S; Rouaen JRC; Pang CNI; Pandher R; Mayoh C; Tang Y; Khan A; Ung C; Tolhurst O; Kankean A; Hayden E; Lehmann R; Shen S; Gopalakrishnan A; Trebilcock P; Gurova K; Gudkov AV; Norris MD; Haber M; Vittorio O; Tsoli M; Ziegler DS
Cell Rep; 2021 Apr; 35(2):108994. PubMed ID: 33852836
[TBL] [Abstract][Full Text] [Related]
13. Experimental analysis of hFACT action during Pol II transcription in vitro.
Hsieh FK; Kulaeva OI; Studitsky VM
Methods Mol Biol; 2015; 1276():315-26. PubMed ID: 25665573
[TBL] [Abstract][Full Text] [Related]
14. Nucleolin is required for RNA polymerase I transcription in vivo.
Rickards B; Flint SJ; Cole MD; LeRoy G
Mol Cell Biol; 2007 Feb; 27(3):937-48. PubMed ID: 17130237
[TBL] [Abstract][Full Text] [Related]
15. The Chaperone FACT and Histone H2B Ubiquitination Maintain S. pombe Genome Architecture through Genic and Subtelomeric Functions.
Murawska M; Schauer T; Matsuda A; Wilson MD; Pysik T; Wojcik F; Muir TW; Hiraoka Y; Straub T; Ladurner AG
Mol Cell; 2020 Feb; 77(3):501-513.e7. PubMed ID: 31837996
[TBL] [Abstract][Full Text] [Related]
16. Histone H2B monoubiquitination functions cooperatively with FACT to regulate elongation by RNA polymerase II.
Pavri R; Zhu B; Li G; Trojer P; Mandal S; Shilatifard A; Reinberg D
Cell; 2006 May; 125(4):703-17. PubMed ID: 16713563
[TBL] [Abstract][Full Text] [Related]
17. The role of FACT in managing chromatin: disruption, assembly, or repair?
Formosa T; Winston F
Nucleic Acids Res; 2020 Dec; 48(21):11929-11941. PubMed ID: 33104782
[TBL] [Abstract][Full Text] [Related]
18. FACT is recruited to the +1 nucleosome of transcribed genes and spreads in a Chd1-dependent manner.
Jeronimo C; Angel A; Nguyen VQ; Kim JM; Poitras C; Lambert E; Collin P; Mellor J; Wu C; Robert F
Mol Cell; 2021 Sep; 81(17):3542-3559.e11. PubMed ID: 34380014
[TBL] [Abstract][Full Text] [Related]
19. A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription.
Ju BG; Lunyak VV; Perissi V; Garcia-Bassets I; Rose DW; Glass CK; Rosenfeld MG
Science; 2006 Jun; 312(5781):1798-802. PubMed ID: 16794079
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase IIα represses transcription by enforcing promoter-proximal pausing.
Herrero-Ruiz A; Martínez-García PM; Terrón-Bautista J; Millán-Zambrano G; Lieberman JA; Jimeno-González S; Cortés-Ledesma F
Cell Rep; 2021 Apr; 35(2):108977. PubMed ID: 33852840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
